COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Heidelberg Pharma's lead ATAC candidate HDP-101 shows promising progress in Phase I/IIa trial for multiple myeloma, including stringent complete remissions. R&D webinar scheduled on 11 Nov 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
Heidelberg Pharma to present new clinical data of lead ADC candidate HDP-101 at the World ADC Congress 2025 and host a webinar. Study results show promising anti-tumor activity in multiple myeloma patients -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Heidelberg Pharma's lead ADC candidate HDP-101 granted Fast Track Designation by US FDA for the treatment of multiple myeloma. Accelerated review for innovative cancer therapy
